Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Serotonin Syndrome 1Neuroendocrine Tumors 1Carcinoma, Hepatocellular 1Carcinoid Tumors, Intestinal 1Carcinoid Tumor 1

Interventions

Everolimus 6pasireotide 5Octreotide 5lanreotide 2ganitumab 2cabozantinib 2Bevacizumab 2surufatinib 1nintedanib 1ibrutinib 1gallium Ga 68 dotatate 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1arginyllysine 1aflibercept 1Temozolomide 1TKM-080301 1Sunitinib 1Sorafenib 1Somatostatin 1Random Allocation 1Ramucirumab 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoid Tumor × Random Allocation × Clear all
NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡